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Abstract
Background: Southern China is a major area for endemic nasopharyngeal carcinoma (NPC). Genetic factors as well
as environmental factors play a role in development of NPC. To investigate the roles of previously described
carcinogen metabolism gene variants for NPC susceptibility in a Han Chinese population, we conducted a case-
control study in two independent study population groups afflicted with NPC in Guangdong and Guangxi
Provinces of southern China.
Methods: Five single nucleotide polymorphisms (SNPs) of CYP2E1-rs2031920, CYP2E1-rs6413432, GSTP1-rs947894,
MPO-rs2333227 and NQO1-rs1800566 were genotyped by PCR-based RFLP, sequencing and TaqMan assay in 358
NPC cases and 629 controls (phase I cohort). Logistic regression analysis was used to estimate odds ratios (OR) and
95% confidence intervals (CI). To confirm our results, sixteen tag SNPs for GSTP1, MPO, NQO1 (which 100% covered
these genes), and 4 functional SNPs of CYP2E1 were genotyped in another cohort of 213 NPC cases and 230
controls (phase II cohort).
Results: No significant associations in NPC risk were observed for the five polymorphisms tested in the phase I
cohort. In an additional stratified analysis for phase I, there was no significant association between cases and
controls in NPC high risk population (EBV/IgA/VCA positive population). Analysis of 14 tagging SNPs within the
same genes in an independent phase II cohort were in agreement with no SNPs significantly associated with NPC.
Conclusions: Our results suggest that polymorphism of CYP2E1, GSTP1, MPO and NQO1 genes does not contribute
to overall NPC risk in a Han Chinese in southern China.
Background
Nasopharyngeal carcinoma (NPC) is rare in most
regions of the world; however it is a common cancer in
southern China, especially in Guangdong and Guangxi
Provinces. The incidence rate of NPC for males is more
than 20 per 100,000 and up to 25-40 per 100,000 in
some areas bordering the Xijiang River and Pearl River
drainages in these two provinces[1,2]. Both environmen-
tal and genetic factors have been associated with the
risk of developing NPC. Epidemiologic studies have
indicated a strong influence for Epstein-Barr virus (EBV)
infection, consumption of salt-preserved fish, exposure
to domestic wood cooking fires, and exposure to occu-
pational solvents in the risk for NPC[3,4]. Accumulating
data have shown that genetic polymorphisms of the
genes responsible for the xenobiotic enzymes which
metabolize carcinogenic compounds underlie individual
variations in cancer risk[5]. Most carcinogens undergo
activation by Phase I enzymes, often as an oxidation
reaction, and detoxification by Phase II enzymes.
CYP2E1 i saP h a s eIe n z y m ei n c l u d e di nt h ec y t o -
chrome P450 superfamily. CYP2E1 plays a major role in
the metabolic activation of nitrosamines. The RsaI
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region has been reported to be associated with increased
risk of lung cancer and lymphomas[6,7]. Two studies
have associated this polymorphism with NPC develop-
ment[8,9]. Glutathione S-transferases (GSTs) are a
group of enzymes involved in Phase II detoxification of
carcinogens. GSTP1 i sam a j o rG S Ti s o f o r m .T h eI l et o
Val substitution at codon 105 of exon 5 variant in
GSTP1 (rs947894) has been investigated for associations
with breast and lung cancer in several studies[10,11].
Four of 22 studies showed a significantly higher risk for
head and neck cancers in persons with the Ile/Val and/
or Val/Val genotypes than in those with the Ile/Ile geno-
types[5].
NQO1 is an enzyme previously shown to detoxify a
number of natural and synthetic compounds and, con-
versely, to activate certain anticancer agents[12]. A sin-
gle nucleotide polymorphism (SNP) C to T at position
609 (rs1800566) in the NQO1 coding region (replacing
proline with serine at codon 187) leads to lower enzyme
activity and has been shown to be associated with
increased risk of myeloid leukemia and bladder carci-
noma[12,13]. Myeloperoxidase (MPO) is an endogenous
oxidant enzyme that generates reactive oxygen species
(ROS). A single G-463A base transition in the MPO
promoter region was identified at the SP1 binding site,
which might modify carcinogen metabolism. The 463A
allele has been associated with reduced mRNA expres-
sion and its transcription activity is approximately 25
times lower than the 463G allele in vitro due to reduced
binding of SP1[14,15]. This polymorphism has also been
reported to be associated with risk for several human
cancers including liver, ovarian, bladder and lung cancer
[16-23].
We conducted a case-control study with 358 NPC
cases and 629 controls from southern China to deter-
mine if these previously implicated polymorphisms were
associated with NPC development. We also investigated
sixteen adjacent tagging SNPs of GSTP1, MPO and
NQO1 (which covered 100% haplotype variation within
these genes), and four SNPs of CYP2E1 (one of which
covered CYP2E1-RsaI polymorphisms) in another inde-
pendent case-control cohort with 213 NPC cases and
230 controls.
Methods
Patients and controls
The NPC cohorts were recruited from areas along the
Xijiang River in Guangdong and Guangxi provinces of
southern China in two collection phases. The phase I
participants were recruited from April 2000 to June
2001. NPC cases were incident or prevalent biopsy-con-
firmed NPC cases with or without IgA antibodies to
EBV capsid antigens (EBV/IgA/VCA). The controls were
the case’s spouse or geographically matched residents
who were EBV/IgA/VCA positive (IgA+) or EBV/IgA/
VCA negative (IgA-) and NPC free at the time of study
enrollment. The phase II participants were recruited
from November 2004 to October 2005. The cases were
incident or prevalent biopsy-confirmed NPC cases who
were IgA+. The controls were IgA+, NPC free at the
time of study enrollment and matched to NPC cases on
age, sex, and district/township of residence. NPC cases
were hospitalized patients at Wuzhou Red Cross Hospi-
tal in Wuzhou City and outpatients at Cangwu Institute
for NPC Control and Prevention in Cangwu County. All
participants self-identified as Han Chinese and self-
reported 6 or more months of residency in Guangdong
or Guangxi Province of China. EBV/IgA/VCA and EBV/
IgA/EA were confirmed by serological testing at the
time of study enrollment. Blood samples were obtained
from 358 NPC cases (239 males and 119 females) and
629 controls (271 males and 358 females) in the phase I
cohort; the mean age was 45 years (± 11 years standard
deviation [SD]) for cases and 46 years (± 10 years SD)
for controls. Blood samples were collected from 213 IgA
+ NPC cases (155 males and 58 female) and 230 IgA+
controls (179 males and 51 females) in the phase II
cohort; the mean age was 45 years (± 9 years SD) for
cases and 45 years (± 10 years SD) for controls (see
Table 1). We excluded persons of minority ethnicity and
those who had blood relatives in either the cases or con-
trols. We also did not allow overlap in participation
between phase I and phase II; that is, persons could not
be in both cohorts. Institutional review board approval
was obtained from all participating institutions and
informed consent was obtained from each study
participant.
Genomic DNA extraction
Phase I DNA was extracted from whole blood or lym-
phoblastoid cell lines (LCL) using QIAamp DNA blood
maxi kit (Qiagen, Valencia, CA, catalog # 51194). More
than 80% of the genotypes were determined from DNA
directly extracted from whole blood. Phase II DNA was
Table 1 Characteristics of participants in a study of
nasopharyngeal carcinoma (NPC) in southern China
Phase I Phase II
Cases Controls Cases Controls
Age(years) 45 ± 11.4 (SD) 46 ± 9.7 (SD) 45 ± 9.1 (SD) 45 ± 9.7 (SD)
Male, % 66.8 (239/358) 43.1 (271/629) 72.8 (155/213) 77.8 (179/230)
IgA+*, % 95.3 (341/358) 44.5 (280/629) 100 (213/213) 100 (230/230)
Total 358 629 213 230
Age was the age at diagnosis of NPC for cases and age of enrollment for
controls.
SD = standard deviation.
* Positive for IgA antibodies to Epstein-Barr virus capsid antigen.
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Chloroform method with Phase Lock Gel tube (Qiagen,
MaXtract High Density, catalog # 129065).
SNP selection and genotyping
For the phase I cohort, five functional SNPs, which pre-
viously were reported associated with NPC or other
cancers, were interrogated for four xenobiotic metabolic
enzyme genes– CYP2E1-RsaI (rs2031920), CYP2E1-DraI
(rs6413432), GSTP1 Ile105Val (rs947894), MPO G-463A
(rs2333227) and NQO1 C609T (rs1800566). For phase I
samples, CYP2E1-rs6413432, GSTP1-rs947894 and
MPO-rs2333227 were genotyped by using a commer-
cially available TaqMan SNP genotyping assay and Gen-
eAmp PCR System 9700 (Applied Biosystems, Foster
City, CA, USA), in accordance with the manufacturer’s
instructions. Sequence detection software was used for
allelic discrimination. CYP2E1-rs2031920 was genotyped
by sequence according to the method available in the
SNP500Cancer Database[24]. NQO1-rs1800566 was gen-
otyped using PCR-restriction fragment length poly-
morphism (RFLP) assay; the polymerase chain reactions
(PCR) were performed in 15 μl volumes containing 10
mM Tris-HCL buffer, 50 mM KCL, 2.0 mM MgCl2, 0.2
m Md N T P ,0 . 2 5m Mo fe a c ho ft h ep r i m e r s( f o r w a r d
primer: GAGACGCTAGCTCTGAACTGAT, reverse
prime: ATTTGAATTCGGGCGTCTGCTG), 40ng
genomic DNA and 5 units of Taq polymerase with ther-
mal cycling conditions of 95°C for 8 minutes followed
by 35 cycles at 94°C for 30 seconds, 62°C for 30 sec-
onds, 72°C for 45 seconds, and then a final extension of
72°C for 8 minutes. The PCR product was digested by
Hinf1 enzyme. The variants (size of bands for each
allele) were determined by a 4% agarose gel assay in
0.5× TBE.
For the phase II cohort, sixteen tagging SNPs for the
same metabolism enzyme genes were selected, which
covered 5,000 base pairs (bp) upstream and 1,000 bp
downstream of these genes. Because two tagging SNPs
in the CYP2E1 gene had a low design score on Illu-
mina measurements, we selected four other SNPs
located in the locus or coding region. One of them,
rs3813867, tracked CYP2E1-RsaI (rs2031920) that was
previously reported associated with NPC[8]. For phase
II samples, sixteen SNPs including rs7927381,
rs6591256 and rs947895 for GSTP1; rs2071409 and
rs2243828 for MPO; rs10517, rs1800566, rs4986998,
rs689452, rs2917667, rs2917666 and rs1469908 for
NQO1; and rs3813867, rs2070673, rs41299426 and
rs41299434 for CYP2E1 were genotyped by Illumina
GoldenGate assay. Fourteen SNPs (all except
rs41299426 and rs41299434 of CYP2E1 which were
excluded due to low minimum allele frequency) were
analyzed as described below.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) compliance was
independently tested for each polymorphism. For
phase I, differences between predicted genotype
frequencies based upon binomially distributed allele
frequency and observed genotype frequencies were
tested using a c
2 goodness of fit test of co-dominant
model. Odd ratios (OR) and 95% confidence intervals
(CIs) were computed by logistic regression. In order to
investigate the influence of EBV/IgA/VCA antibody
status, we also analyzed the associations between poly-
morphisms and the occurrence of NPC in an EBV/IgA/
VCA positive subpopulation.T h er e s u l t so ft h ep h a s eI
analysis were adjusted for age and gender. For the phase
II cohort, the linear trend chi-square tests were used to
test for additive allele effects on the disease penetrance.
Odds ratios are calculated based on the 2 × 2 table of
allele-by-trait counts. All statistics were calculated in the
statistical package SAS/SAS Genetics version 9.1.3.
Results
Association results in phase I cohort
Five SNPs in four metabolism enzyme loci genes were
genotyped in 358 nasopharyngeal carcinoma cases and
629 controls. Over 95% of NPC cases (n = 341) and
45% of the controls were positive for EBV/IgA/VCA
antibodies in the phase I cohort (Table 1). Each of the
five SNPs demonstrated conformance to Hardy-Wein-
berg equilibrium in the phase I cohort. The rates of suc-
cessful genotyping were 81.1% for GSTP1-rs947894,
88.4% for MPO-rs2333227, 95.2% for CYP2E1-
rs6413432, 98.0% for NQO1-rs1800566 and 99.3% for
CYP2E1-rs2031920. The genotype distributions, odds
ratios, 95% confidence intervals and p-values for the
association of five polymorphisms in cases and controls
are shown in Table 2. No significant differences in the
frequencies of genotypes for the five SNPs were
observed between cases and controls. We also stratified
the analysis by EBV/IgA/VCA status to test for joint
effects. No significant differences in frequencies of geno-
types for these SNPs were found between EBV/IgA/
VCA-positive cases and controls in our study population
(Table 2).
Association results in phase II cohort
All cases (N = 213) and controls (n = 230) in the phase
II cohort were positive for EBV/IgA/VCA antibodies
(Table 1). Genotypes were obtained for more than 95%
of the participants for 16 SNPs in this cohort. The
rs41299426 and rs41299434 of CYP2E1 with minor
allele frequencies less than 1% were excluded from ana-
lysis. The genotype frequencies of the other 14 SNPs
conformed to Hardy-Weinberg equilibrium. Table 3 lists
the information of SNPs, minor allele frequencies
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between cases and controls. There were no significant
differences for these polymorphisms between cases and
controls in the NPC phase II cohort (p = 0.08-0.89).
Discussion
Five genetic variants of CYP2E1, GSTP1, MPO and
NQO1 were genotyped in 358 NPC cases and 629 con-
trols (phase I cohort) from NPC high incidence regions
in southern China. No significant association with risk
of NPC was observed (Table 2). A previous study
found the highest risk population for NPC in southern
China is EBV/IgA/VCA antibody positive (IgA+)[4]. To
investigate potential influence of factors exclusive of
EBV/IgA/VCA antibody development, we stratified the
analysis in the phase I cohort to compare 341 NPC
cases with IgA+ to 280 IgA + controls. Still, no signifi-
cant association of genotypes examined with NPC risk
was noted (Table 2). To attempt replication from a
previous report of a 2.6-fold increased risk of NPC
among individuals homozygous for TT of CYP2E1-RsaI
(rs2031920) variant[8], the tagging SNPs for GSTP1,
MPO,a n dNQO1 (which 100% covered these genes)
and four SNPs of CYP2E1 (which covered CYP2E1-
RsaI (rs2031920) variant) were genotyped in a second
independent cohort of 213 IgA+ NPC cases and 230
IgA+ controls (phase II cohort). Similarly no signifi-
cant association was found between polymorphisms
Table 2 Odds ratios for the association of five polymorphisms with risk of nasopharyngeal carcinoma (NPC) in
southern China (Phase I cohort)
Gene-SNP Genotype Cases (%) Controls (%) OR 95%CI p value
All subjects* (n = 358) (n = 629)
CYP2E1-rs2031920 CC 228 (64.0) 412 (66.0) 1.0
CT 108 (30.3) 186 (29.8) 1.06 0.78-1.42 0.72
TT 20 (5.6) 26 (4.2) 1.21 0.63-2.34 0.57
CYP2E1-rs6413432 TT 188 (56.0) 360 (59.6) 1.0
AT 121 (36.0) 202 (33.4) 1.10 0.82-1.49 0.52
AA 27 (8.0) 42 (7.0) 1.07 0.61-1.85 0.82
GSTP1-rs947894 AA 181 (65.1) 346 (66.3) 1.0
AG 84 (30.2) 159 (30.5) 0.98 0.70-1.37 0.91
GG 13 (4.7) 17 (3.3) 1.41 0.65-3.03 0.39
MPO-rs2333227 GG 223 (69.0) 381 (69.3) 1.0
GA 93 (28.8) 157 (28.6) 0.95 0.69-1.30 0.74
AA 7 (2.2) 12 (2.2) 1.15 0.43-3.07 0.78
NQO1-rs1800566 CC 96 (27.7) 169 (27.3) 1.0
CT 159 (45.8) 320 (51.6) 0.87 0.63-1.21 0.41
TT 92 (26.5) 131 (21.1) 1.18 0.81-1.72 0.39
EBV/IgA/VCA+** (n = 341) (n = 280)
CYP2E1-rs2031920 CC 214 (63.1) 186 (66.9) 1.0
CT 105 (31.0) 82 (29.5) 1.10 0.77-1.58 0.59
TT 20 (5.9) 10 (3.6) 1.39 0.61-3.15 0.43
CYP2E1-rs6413432 TT 175 (54.7) 160 (58.8) 1.0
AT 118 (36.9) 93 (34.2) 1.12 0.79-1.60 0.52
AA 27 (8.4) 19 (7.0) 1.03 0.54-1.98 0.92
GSTP1-rs947894 AA 172 (65.4) 168 (69.7) 1.0
AG 79 (30.0) 67 (27.8) 1.09 0.73-1.63 0.66
GG 12 (4.6) 6 (2.5) 1.80 0.65-5.01 0.26
MPO-rs2333227 GG 217 (70.2) 159 (66.5) 1.0
GA 85 (27.5) 72 (30.1) 0.84 0.57-1.23 0.37
AA 7 (2.3) 8 (3.4) 0.77 0.27-2.22 0.63
NQO1-rs1800566 CC 91 (27.6) 73 (26.6) 1.0
CT 151 (45.8) 139 (50.6) 0.88 0.60-1.31 0.53
TT 88 (26.7) 63 (22.9) 1.11 0.70-1.74 0.66
OR = odds ratio.
CI = confidence interval.
*Cases and controls in this group were a mix of IgA+ and IgA- individuals.
**Cases and controls in this group were only IgA+ individuals.
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and risk of NPC (table 3).
Our results did show a trend for slightly increased risk
of NPC with T allele of CYP2E1-RsaI (OR = 1.06 for CT
and OR = 1.21 for TT), and a slightly greater risk in
individuals with IgA antibodies to EBV capsid antigen
(OR = 1.10 for CT and OR = 1.39 for TT), but no sta-
tistically significant association in either situation (Table
2). The replication result of CYP2E1-rs3813867 which
covered CYP2E1-RsaI from the phase II cohort indicated
a similar trend (OR = 1.34); again this did not reach the
level of statistical significance (Table 3). Although
numerous studies have examined the association of the
polymorphisms for CYP2E1, GSTP1, MPO and NQO1
genes with various tumors, very few have investigated
the associations between variants of these genes and the
risk of nasopharyngeal carcinoma.
Hildesheim et al genotyped 378 NPC cases and 320
controls employing PCR-RFLP assay and reported that
CYP2E1 may be a susceptibility gene for NPC develop-
ment in Taiwan[8]. This study has been cited in the lit-
erature over 100 times through the end of 2009. We
attempted to replicate this study using the PCR-RFLP
assay in our phase I cohort; the bands at agarose gel
appeared distinct. However, the analysis results showed
that the distribution of genotype was a significant depar-
ture from the Hardy-Weinberg equilibrium. Since the
TaqMan assay is unavailable for rs2031920, we re-geno-
typed this SNP by direct sequencing. The results shown
in our study are sequencing results (Table 2); however,
our findings, which had similar statistical power to the
Hildesheim et al study, did not confirm the association
observed in the Taiwan study. To further expand our
results, an adjacent SNP variant (CYP2E1-rs3813867)
which tracks the CYP2E1- rs2031920 by linkage disequi-
librium was investigated in the phase II cohort. The
results obtained from this analysis were shown similarly
insignificant. From our experience, sequencing assay
should be more accurate than the PCR-RFLP. Differ-
ences in technique may be the cause of the discrepan-
cies between the results from our study and the Taiwan
study[8]. A study conducted in Thailand also showed a
slightly increased risk of NPC for CYP2E1- rs2031920;
again, the result was not statistically significant[9], simi-
lar to results of our study.
Over 200 studies have investigated the association
between the polymorphism of GSTP1 and different can-
cers, however only one study analyzed this gene region
for nasopharyngeal carcinoma. Our results found no sig-
nificant association between genetic polymorphism of
GSTP1 and the risk of NPC, similar to a previous report
[25]. Our results also showed that there were no signifi-
cant associations between polymorphisms of MPO,
NQO1 and nasopharyngeal carcinoma in two cohorts
(Tables 2, 3).
Our findings are subject to certain limitations. The
etiology of nasopharyngeal carcinoma is influenced by
many factors, both genetic and environmental. The
Table 3 Association of CYP2E1, GSTP1, MPO and NQO1 with risk of nasopharyngeal carcinoma (NPC) in an IgA+
population in southern China (Phase II cohort)
SNP-ID Allele SNP-Type MAF† Cases Controls OR 95%CI Trend p
CYP2E1
rs3813867 C/G Locus-region 0.219 207 226 1.34 0.97-1.86 0.08
rs2070673 A/T Locus-region 0.450 212 229 0.95 0.73-1.24 0.69
GSTP1
rs7927381 C/T ~4k upstream 0.163 211 230 1.15 0.80-1.64 0.46
rs6591256 A/G Locus-region 0.175 210 226 1.24 0.87-1.76 0.24
rs947895 A/C Locus-region 0.182 208 226 0.98 0.69-1.38 0.89
MPO
rs2071409 A/C intron 0.183 207 229 0.83 0.59-1.17 0.28
rs2243828 A/G downstream 0.175 200 221 0.74 0.52-1.06 0.12
NQO1
rs10517 C/T mRNA-UTR 0.296 210 224 0.83 0.62-1.11 0.21
rs1800566 C/T Conding-nonsyn 0.474 205 225 0.90 0.69-1.18 0.46
rs4986998 C/T intron 0.041 205 227 1.05 0.53-2.06 0.89
rs689452 C/G intron 0.360 213 230 0.97 0.74-1.28 0.83
rs2917667 C/T downstream 0.360 213 230 1.03 0.78-1.36 0.81
rs2917666 C/G downstream 0.156 213 230 0.88 0.61-1.27 0.50
rs1469908 A/G downstream 0.164 209 230 1.16 0.81-1.66 0.41
OR = odds ratio.
CI = confidence interval.
†Minor allele frequency
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ited effect on NPC. However, although our had similar
statistical power as Hildesheim et al, due to different
study populations, geographic locations, and other
unknown factors, our study may not be sufficiently
robust to refute the previous study[8]. Additional larger
population studies are necessary to determine a defini-
tive answer. Another limitation is that no environmental
exposure data (such as smoking history, salt-preserved
fish or alcohol consumption, exposure to domestic
cooking fires, etc.) is available for our phase I cohort.
The environmental exposure data is available for the
phase II cohort, and we did conduct an analysis adjusted
for salt fish consumption, as well as exposure to domes-
tic cooking fire and occupational solvents, for the phase
II genotype data. Still, no significant association was
found (data not shown).
Conclusions
We could not confirm the previously reported increased
risk of NPC among individuals homozygous for TT of
CYP2E1-RsaI (rs2031920) variant. This may be in part
due to our use of a different assay method; however, the
method we used is now considered the most accurate
available. Our results suggest that polymorphism of
CYP2E1, GSTP1, MPO and NQO1 genes do not contri-
bute appreciably to overall NPC risk in a Han popula-
tion from southern China. Further studies examining
the interaction of genetic and environmental factors on
the incidence of nasopharyngeal carcinoma are needed.
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